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Abstract
Background
Nevirapine-based antiretroviral therapy is the predominant (and often the only) 
regimen available for children in resource-limited settings. Nevirapine resistance 
after exposure to the drug for prevention of maternal-to-child human immunode-
ficiency virus (HIV) transmission is common, a problem that has led to the recom-
mendation of ritonavir-boosted lopinavir in such settings. Regardless of whether 
there has been prior exposure to nevirapine, the performance of nevirapine versus 
ritonavir-boosted lopinavir in young children has not been rigorously established.
Methods
In a randomized trial conducted in six African countries and India, we compared 
the initiation of HIV treatment with zidovudine, lamivudine, and either nevirapine 
or ritonavir-boosted lopinavir in HIV-infected children 2 to 36 months of age who 
had no prior exposure to nevirapine. The primary end point was virologic failure or 
discontinuation of treatment by study week 24.
Results
A total of 288 children were enrolled; the median percentage of CD4+ T cells was 
15%, and the median plasma HIV type 1 (HIV-1) RNA level was 5.7 log10 copies per 
milliliter. The percentage of children who reached the primary end point was sig-
nificantly higher in the nevirapine group than in the ritonavir-boosted lopinavir 
group (40.8% vs. 19.3%; P<0.001). Among the nevirapine-treated children with vi-
rologic failure for whom data on resistance were available, more than half (19 of 32) 
had resistance at the time of virologic failure. In addition, the time to a protocol-
defined toxicity end point was shorter in the nevirapine group (P = 0.04), as was the 
time to death (P = 0.06).
Conclusions
Outcomes were superior with ritonavir-boosted lopinavir among young children 
with no prior exposure to nevirapine. Factors that may have contributed to the sub-
optimal results with nevirapine include elevated viral load at baseline, selection for 
nevirapine resistance, background regimen of nucleoside reverse-transcriptase inhibi-
tors, and the standard ramp-up dosing strategy. The results of this trial present 
policymakers with difficult choices. (Funded by the National Institute of Allergy and 
Infectious Diseases and others; P1060 ClinicalTrials.gov number, NCT00307151.)
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New antiretroviral drugs and drug classes have markedly advanced the treat-ment of human immunodeficiency virus 
(HIV) infection in children. In resource-limited 
settings, where most HIV-infected children live, 
therapeutic options are restricted by financial 
and logistic constraints. Nevirapine is an impor-
tant component of long-term therapy because it 
is stable at high temperatures, available in fixed-
dose combinations, and relatively inexpensive, 
and its use is based on extensive experience and 
an acceptable safety profile in the pediatric pop-
ulation. Often, it is the only option available for 
infants and children.
Randomized studies have shown that regi-
mens incorporating ritonavir-boosted lopinavir 
(both protease inhibitors) are superior to nevira- 
pine-based regimens in the treatment of moth-
ers and infants who were previously exposed to 
single-dose nevirapine for the prevention of peri-
natal HIV transmission.1,2 The World Health 
Organization (WHO) guidelines for antiretrovi-
ral treatment (ART) now recommend ritonavir-
boosted lopinavir for the initial treatment of 
children younger than 2 years of age who have 
previously been exposed to single-dose nevira- 
pine.3 Nevirapine continues to be recommended 
for initial therapy in children without prior ex-
posure to nevirapine; however, there has been 
no randomized trial comparing ritonavir-boost-
ed lopinavir–based ART and nevirapine-based 
ART in such children.
The P1060 study was designed as two parallel, 
randomized clinical trials comparing nevirapine 
with ritonavir-boosted lopinavir, in addition to 
zidovudine and lamivudine, in HIV-infected, ART-
eligible children between 2 and 36 months of 
age. We previously published the findings in 
cohort 1 of the study, which comprised children 
with documented exposure to single-dose nevi-
rapine.1 Here, we report the findings in cohort 2, 
which comprised children without previous ne-
virapine exposure.
METHODS
Patient Population and Study Design
Children with HIV infection were eligible for the 
study if they had not previously been exposed to 
antiretroviral agents (except for those used to 
prevent mother-to-child transmission of HIV), if 
they required treatment according to WHO crite-
ria, and if their baseline level of plasma HIV type 1 
(HIV-1) RNA was above 5000 copies per millili-
ter. Children (and their mothers) could not have 
had previous exposure to non-nucleoside reverse-
transcriptase inhibitors (NNRTIs) such as nevir- 
apine or efavirenz (hereinafter referred to as an 
absence of exposure to nevirapine).
The children were stratified by age (2 to <6, 
6 to <12, or 12 to 36 months) and randomly as-
signed in equal numbers to either nevirapine or 
ritonavir-boosted lopinavir, combined with zidovu-
dine and lamivudine. Nevirapine was initially 
given in a dose of 4 mg per kilogram of body 
weight once daily for 14 days, with a dose of 
7 mg per kilogram twice daily thereafter (the 
dose approved by the Food and Drug Administra-
tion). An amendment to the protocol (September 
4, 2007) increased the nevirapine dose to 160 to 
200 mg per square meter of body-surface area 
(once daily for 14 days, then twice daily) in line 
with newly instituted WHO recommendations.
Children were enrolled at one site in India 
and at nine sites across sub-Saharan Africa (four 
in South Africa and one each in Zimbabwe, 
Zambia, Malawi, Uganda, and Tanzania). The 
study was approved by the ethics review com-
mittee at each site, the Ministries of Health 
(where appropriate), and the institutional review 
board at each partner institution in the United 
States. Each child’s parent or legal guardian pro-
vided written informed consent. Study visits and 
laboratory testing were conducted as previously 
described.1
All the authors vouch for the completeness and 
accuracy of the data presented. The study was 
conducted in accordance with the protocol, avail-
able with the full text of this article at NEJM.org. 
The antirectroviral drugs used in this study were 
donated by Abbott, Boehringer Ingelheim, and 
GlaxoSmithKline. Representatives of these three 
pharmaceutical manufacturers participated in 
early discussions of the trial design but not in 
final design decisions or in trial implementation 
or analyses.
Study End Points
The primary study end point was treatment fail-
ure by 24 weeks, defined as virologic failure or 
permanent discontinuation of the nevirapine or 
ritonavir-boosted lopinavir component of the 
treatment regimen for any reason (concomitant 
tuberculosis therapy, death, or another reason). 
Virologic failure was defined as a confirmed 
plasma HIV-1 RNA level that was less than 1 log10 
The New England Journal of Medicine 
Downloaded from nejm.org at STELLENBOSCH UNIVERSITY on November 25, 2019. For personal use only. No other uses without permission. 
 Copyright © 2012 Massachusetts Medical Society. All rights reserved. 
Th e  new england journal  o f  medicine
n engl j med 366;25 nejm.org june 21, 20122382
copies per milliliter below the baseline level at 12 
to 24 weeks after treatment initiation, or a con-
firmed plasma HIV-1 RNA level of more than 400 
copies per milliliter at 24 weeks. Toxicity end 
points are defined in the protocol.
Secondary end points included confirmed vi-
rologic failure or death by week 24, confirmed 
virologic failure (with virologic failure defined 
as above or as a confirmed viral rebound to 
>4000 copies per milliliter after week 24) or 
death during the follow-up period, and a com-
posite of virologic failure or discontinuation of 
the study treatment during the follow-up period. 
Data for children lost to follow-up were censored 
for the virologic failure end point at the date of 
the last available HIV-1 RNA measurement.
Statistical Analysis
The analysis included all children in cohort 2 who 
started the study treatment. Four children who 
had previously been exposed to nevirapine were 
incorrectly assigned to cohort 2. These four chil-
dren were included in all analyses; sensitivity 
analyses that excluded them showed similar re-
sults. Since only four infants were enrolled in the 
youngest age stratum (2 to <6 months), children 
in the two youngest strata were combined for all 
the analyses.
Rates of the primary end point and of viro-
logic failure at week 24 were calculated from 
Kaplan–Meier curves for each age stratum. The 
primary analysis was based on a weighted aver-
age of rates across age strata, with weights equal 
to the inverse of the variance of the stratum-
specific rate. Unweighted rates (i.e., with age 
stratification ignored) were also evaluated. Age-
stratified Cox proportional-hazards models were 
used to compare time-to-event end points (in ad-
justed and unadjusted analyses) and to evaluate 
whether differences between randomly assigned 
treatments varied across subgroups by including 
a treatment-by-subgroup interaction variable. Pre-
specified subgroups were classified according to 
age, sex, initial dose of nevirapine, HIV subtype, 
and type of documentation supporting the ab-
sence of prior exposure to nevirapine, as well as 
baseline HIV-1 RNA level, percentage of CD4+ 
T cells, CD4+ count, and WHO disease stage.
Safety information was reported while the 
children were receiving the study treatment (as- 
treated analysis). Summaries of adverse events 
according to the highest grade for each type of 
event were tabulated. Changes from baseline to 
weeks 24 and 48 in cholesterol levels, triglycer-
ide levels, CD4+ counts and percentages, Cen-
ters for Disease Control and Prevention z scores 
for height and weight (www.cdc.gov/growthcharts), 
and body-mass index (BMI) were compared ac-
cording to treatment with the use of t-tests (un-
adjusted) and linear regression analyses adjusted 
for entry value. Intention-to-treat analyses were 
performed for immunologic and growth out-
comes, and as-treated analyses were performed 
for lipid data. Two-sided P values, unadjusted for 
interim analyses or multiple comparisons, are 
reported.
RESULTS
Study Participants, Follow-up, and Treatment 
Adherence
A total of 288 children were enrolled between 
November 23, 2006, and March 19, 2010, with 
follow-up planned to continue until March 2011. 
On October 27, 2010, when the 24-week follow-
up for all children was complete, the data and 
safety monitoring board performed a review and 
recommended unblinding of the data and release 
of the results, since the comparisons of the two 
treatments for the primary end point had met 
prespecified stopping guidelines.
Reported analyses are based on data collected 
through October 27, 2010, for the 147 children 
randomly assigned to nevirapine and the 140 as-
signed to ritonavir-boosted lopinavir; 1 child in 
the ritonavir-boosted lopinavir group never started 
therapy and was therefore not included (see Table 
S1 in the Supplementary Appendix, available at 
NEJM.org). The median follow-up period was 
72 weeks (interquartile range, 48 to 120). At base-
line, 210 children (73.2%) were 12 months of 
age or older, with a median age of 1.7 years 
(Table 1). The children had relatively advanced 
HIV disease, with a median HIV-1 RNA level of 
535,632 copies per milliliter, a median of 15% 
CD4+ T cells, and median z scores of −2.6 for 
weight and −2.3 for height. The majority of HIV 
infections (212 of 265 [80.0%]) were subtype C. 
Median adherence to therapy was 100% for the 
initial 24 weeks of treatment, according to reports 
by caregivers, with no significant differences be-
tween the two treatment groups (P = 0.16). Care-
givers reported adherence of 95% or higher for 
80.3% of the children who received nevirapine, 
as compared with 90.0% of those who received 
ritonavir-boosted lopinavir.
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Primary End Point
The percentage of children who reached the pri-
mary end point (i.e., virologic failure or discon-
tinuation of the study treatment for any reason, 
including death, by 24 weeks) was significantly 
higher in the nevirapine group than in the rito-
navir-boosted lopinavir group (40.8%, vs. 19.3%; 
P<0.001) (Table 2). The relative contributions of 
these end points were similar in the two treat-
ment groups: 55.6% of the children in the ritona-
vir-boosted lopinavir group who reached the pri-
mary end point discontinued treatment before 
virologic failure, as compared with 45.0% in the 
nevirapine group (Table S2 in the Supplementary 
Appendix). The findings were similar across age 
strata (between-group difference in the percentage 
of children who reached the primary end point, 
21.5 percentage points across both age strata, 
22.0 percentage points for children younger than 
12 months of age, and 21.3 percentage points for 
those 12 months of age or older) (Table 2 and 
Fig. 1A and 1B).
The results of primary end point analyses ad-
justed for age, sex, severity of HIV disease (based 
on WHO stage, percentage of CD4+ T cells, and 
HIV-1 RNA level), nevirapine dose at entry, 
documentation of prior single-dose nevirapine 
exposure (to prevent mother-to-child transmis-
sion), and HIV subtype were similar to the re-
sults of unadjusted analyses; only baseline HIV-1 
RNA level was a significant predictor of the 
primary end point after adjustment for treat-
ment (P = 0.03). Tests for interaction showed 
no evidence that the difference between treat-
ment groups in the primary end point varied 
across subgroups (P = 0.31 for age, P = 0.18 for 
nevirapine dose, and P≥0.10 for all other sub-
groups).
Table 1. Baseline Characteristics of the Children.
Characteristic
Nevirapine Group 
(N = 147)
Ritonavir-Boosted Lopinavir Group 
(N = 140)
Total 
(N = 287)
Age <12 Mo 
(N = 41)
Age ≥12 Mo 
(N = 106)
All
(N = 147)
Age <12 Mo 
(N = 36)
Age ≥12 Mo 
(N = 104)
All
(N = 140)
Age — yr
Median 0.7 2.1 1.8 0.7 1.9 1.7 1.7
10th–90th percentile 0.5 to 1.0 1.3 to 2.9 0.7 to 2.9 0.5 to 0.9 1.3 to 2.8 0.6 to 2.7 0.6 to 2.8
Male sex — no. (%) 23 (56.1) 46 (43.4) 69 (46.9) 19 (52.8) 49 (47.1) 68 (48.6) 137 (47.7)
Breast-fed — no. (%) 30 (73.2) 88 (83.0) 118 (80.3) 33 (91.7) 82 (78.8) 115 (82.1) 233 (81.2)
Weight — z score
Median −2.1 −2.7 −2.6 −1.9 −2.8 −2.7 −2.6
10th–90th percentile −4.6 to 0.0 −5.3 to −0.6 −5.3 to −0.2 −3.9 to −0.5 −5.2 to −0.7 −5.2 to −0.5 −5.2 to −0.4
Height — z score
Median −1.8 −2.5 −2.3 −1.6 −2.5 −2.3 −2.3
10th–90th percentile −3.2 to 0.1 −4.0 to −0.8 −4.0 to −0.4 −3.7 to 0.2 −4.2 to −0.8 −4.0 to −0.3 −4.0 to −0.4
CD4+ T cells — %
Median 16.0 14.0 14.9 18.9 14.4 15.0 15.0
10th–90th percentile 11.0 to 28.0 8.1 to 23.0 8.8 to 24.0 9.0 to 29.5 7.0 to 24.0 7.9 to 26.1 8.0 to 25.2
Plasma HIV-1 RNA — log10 copies/ml*
Median 5.9 5.6 5.7 5.9 5.7 5.8 5.7
10th–90th percentile 5.0 to 5.9 4.8 to 5.9 4.9 to 5.9 4.8 to 5.9 4.6 to 5.9 4.7 to 5.9 4.8 to 5.9
WHO stage III or IV — no. (%)† 21 (51.2) 71 (67.0) 92 (62.6) 19 (52.8) 69 (66.3) 88 (62.9) 180 (62.7)
Documentation of no prior exposure to 
nevirapine based only on oral  
report — no. (%)‡
10 (24.4) 9 (8.5) 19 (12.9) 5 (13.9) 17 (16.3) 22 (15.7) 41 (14.3)
* Data for HIV-1 RNA counts were censored at the upper limit of the assay (5.9 log10 copies per milliliter).
† WHO denotes World Health Organization.
‡ For all other infants, additional forms of documentation were available showing that they had not previously been exposed to nevirapine.
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Secondary Analyses
Rates of virologic failure or death by week 24 
were 15.6 percentage points higher in the nevi-
rapine group than in the ritonavir-boosted lopi-
navir group (95% confidence interval [CI], 6.3 to 
24.8; P = 0.001) (Fig. 1C and 1D). The hazard ratio 
for time to virologic failure or death by week 24 
for children in the nevirapine group, as com-
pared with those in the ritonavir-boosted lopina-
vir group, was 2.51 (95% CI, 1.41 to 4.47; P<0.01); 
adjusted analyses had similar results. Analyses of 
time to virologic failure or discontinuation of 
study treatment and time to virologic failure or 
death during the follow-up period significantly 
favored the ritonavir-boosted lopinavir group 
(Fig. 1). For all study end points, the difference 
between the treatment groups had been largely 
established by 24 weeks. By 48 weeks, 81 of 108 
children (75.0%) randomly assigned to nevirap-
ine had HIV-1 RNA levels below 400 copies per 
milliliter, as compared with 101 of 119 children 
(84.9%) randomly assigned to ritonavir-boosted 
lopinavir (P = 0.06).
At study entry, 58 of 287 mothers (20.2%) were 
breast-feeding their infants (18.4% of the moth-
ers of infants in the nevirapine group and 22.1% 
of those in the ritonavir-boosted lopinavir group), 
and none of the mothers were receiving ART. 
During study follow-up, mothers of 6 infants in 
the nevirapine group and 5 infants in the ritona-
vir-boosted lopinavir group started ART, which 
in all cases included nevirapine. Only one of 
these children (in the ritonavir-boosted lopinavir 
group) had virologic failure, making it unlikely 
that maternal use of nevirapine-based ART in-
fluenced the study results. Multiple analyses 
showed that the initial nevirapine dose had no 
effect on hazard ratios for any end point or tox-
icity outcome.
Resistance to Antiretroviral Agents
Accurate assignment to cohort 2 was dependent 
on the absence of prior maternal or infant expo-
sure to NNRTIs. The results of baseline testing 
for resistance to antiretroviral agents (ViroSeq 
HIV-1 Genotyping System for population sequenc-
ing [Celera]) supported the assignments. Only 5 of 
257 children (2.0%) with samples that could be 
evaluated had mutations conferring nevirapine 
resistance (Y181C in 4 and K103N in 1) at base-
line; only 1 of these 5 children was randomly 
assigned to the nevirapine group.
Among the 45 children in the nevirapine group 
who had virologic failure, resistance data were 
available at the time of failure for 32 children 
(for 23 by the visit at 24 weeks). At the time of 
virologic failure, 11 children had no detectable 
resistance, 17 had resistance to both nucleoside 
reverse-transcriptase inhibitors (NRTIs) and 
NNRTIs, 2 had resistance only to NRTIs, and 
Table 2. Rate of the Primary End Point, According to Treatment Group and Age.*
Variable Nevirapine
Ritonavir-Boosted  
Lopinavir Group
Between-Group
Difference
(95% CI)† P Value
All Children
Rate of  
End Point All Children
Rate of  
End Point
no. % no. % percentage points
Age
<12 mo 41 41.5 36 19.4 22.0 (2.2–41.9) 0.03
≥12 mo 106 40.6 104 19.2 21.3 (9.3–33.4) 0.001
All children
Unweighted analysis 147 40.8 140 19.3 21.5 (11.2–31.8) <0.001
Weighted analysis 147 40.8 140 19.3 21.5 (11.2–31.8) <0.001
* The rates of the primary end points (virologic failure or treatment discontinuation by study week 24) were estimated 
with the use of Kaplan–Meier methods. The weighted analysis was the primary study comparison; in the unweighted 
analysis, children were not stratified according to age. CI denotes confidence interval.
† The between-group difference is the rate in the nevirapine group minus the rate in the ritonavir-boosted lopinavir group.
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Figure 1. Time to Primary End Point or Death, According to Treatment and Age Group.
The time to the primary end point of virologic failure or discontinuation of treatment by study week 24 is shown for children 2 months to 
less than 12 months of age (Panel A) and for those 12 months of age or older (Panel B). The time to virologic failure or death is also 
shown for these two age groups (Panels C and D, respectively).
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2 had resistance only to NNRTIs. Among chil-
dren in the ritonavir-boosted lopinavir group, 
resistance data were available for 20 of 29 chil-
dren with virologic failure at the time of failure: 
9 had no detectable resistance, and 11 had resis-
tance to NRTIs (1 of whom also had resistance 
to nelfinavir).
Safety Analysis and Adverse Events
There were 13 deaths in the study: 10 in the ne-
virapine group and 3 in the ritonavir-boosted 
lopinavir group (hazard ratio with nevirapine, 
3.41; 95% CI, 0.94 to 12.40; P = 0.06 by the Wald 
test; P = 0.05 by exact log-rank test). Seven of the 
deaths in the nevirapine group occurred within 
the first 12 weeks of the study (Fig. S1 in the 
Supplementary Appendix). In 9 children, the pri-
mary cause of death was infection: gastroenteri-
tis and diarrhea with marasmus (in 4 children), 
pneumonia (in 2), sepsis associated with burns 
and kwashiorkor (in 2), and malaria (in 1); the 
cause of death was unknown in 1 child. Among 
the 3 deaths in children receiving ritonavir-
boosted lopinavir, 1 was due to measles, 1 to 
pneumonia and cardiac failure, and 1 to gastro-
enteritis and marasmus.
Protocol-defined toxicity end points occurred 
in 19 children: 14 in the nevirapine group and 
5 in the ritonavir-boosted lopinavir group (Table 
S3 in the Supplementary Appendix). The time to 
a protocol-defined toxicity end point was shorter 
in the nevirapine group than in the ritonavir-
boosted lopinavir group (hazard ratio, 3.00; 95% 
CI, 1.06 to 8.21; P = 0.04). The primary differences 
between treatment groups were higher rates of 
dermatologic and hepatic toxicity end points as-
sociated with nevirapine treatment (Tables S3 and 
S4 in the Supplementary Appendix). Changes in 
cholesterol and triglyceride levels at 24 and 48 
weeks, adjusted for values at entry, did not differ 
significantly between the two treatment groups.
Immunologic and Growth Responses
Changes in the CD4+ count and percentage, 
weight and height z scores, and BMI from base-
line to week 24 and to week 48 were compared 
according to treatment, with and without adjust-
ment for baseline value and age stratum. Mean 
values improved for all outcomes in both treat-
ment groups; between-group differences were sig-
nificant only for adjusted changes in the z score 
for weight (P = 0.01 at week 24 and P = 0.01 at week 
48) and BMI (P = 0.02 at week 24 and P = 0.03 at 
week 48) and favored the nevirapine group (Fig. 
2, and Table S5 in the Supplementary Appendix).
DISCUSSION
The results of this randomized clinical trial, 
which compared nevirapine-based ART and rito-
navir-boosted lopinavir–based ART for the initial 
treatment of HIV-infected children, challenge 
our current approach. For infants and young chil-
dren, regardless of whether they were previously 
exposed to nevirapine, we now have evidence of 
the superiority of ritonavir-boosted lopinavir–
based regimens over nevirapine-based regimens 
in terms of both efficacy and safety.
Nevirapine-based treatment is currently the 
choice for first-line ART in most countries where 
resources are limited and is often the only read-
ily available option. Recent data in HIV-infected 
women have provided support for the continued 
use of nevirapine as a first-line treatment option. 
The Optimal Combination Therapy after Nevira- 
pine Exposure (OCTANE) A5208 trial, which had 
a design parallel to that of the P1060 study, 
showed that nevirapine, administered as the 
initial treatment in HIV-infected women without 
prior exposure to single-dose nevirapine, was 
noninferior to ritonavir-boosted lopinavir with 
respect to virologic failure or death2; however, 
nevirapine was associated with a poorer safety 
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Figure 2. Change in Weight from Baseline, According to Week of Treatment.
Mean changes in z scores for weight from baseline are shown. The vertical 
bars represent 95% confidence intervals.
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profile. The treatment regimen included tenofo-
vir and emtricitabine, which may be more potent 
than zidovudine and lamivudine, the agents used 
in the P1060 study. In addition, the PENPACT 1 
(Paediatric European Network for Treatment of 
AIDS [PENTA 9]/Pediatric AIDS Clinical Trials 
Network [PACTG] 390) trial, conducted in Europe, 
the United States, and South America, showed 
equivalent outcomes when treatment was initiated 
with an NNRTI-based regimen or a protease-
inhibitor–based regimen.4 The PENPACT 1 trial 
differed substantially from the P1060 trial in sev-
eral respects: it enrolled children at a median 
age of 6.5 years, with a median viral load of 5.1 
log10 copies per milliliter; the primary end point 
was virologic only (without consideration of 
treatment changes); and it allowed investigators 
to choose the NNRTIs (efavirenz was chosen in 
62% of the cases) and protease inhibitors (which 
were equally divided between nelfinavir and 
ritonavir-boosted lopinavir). The P1060 study di-
rectly compared nevirapine-based treatment and 
ritonavir-boosted lopinavir–based treatment in 
children who were younger than 3 years of age.
Why did nevirapine fare less well than ritonavir-
boosted lopinavir among the infants in our 
study? One important factor may be the high 
plasma HIV-1 RNA levels commonly seen during 
infancy (median for the overall cohort, 536,000 
copies per milliliter), which make viral suppres-
sion difficult. Even with optimal ART viral decay 
kinetics, the time to achievement of an undetect-
able plasma virus level will be longer for infants 
than for older children and adults, who have 
lower viral loads.5,6 It is plausible that the use of 
agents for which single-gene mutations result in 
resistance (e.g., nevirapine) may be suboptimal 
in the presence of high viral replication and a 
prolonged time to viral suppression, which may 
confer a predisposition to the emergence of re-
sistance. In the P1060 study, more than half the 
children in the nevirapine group who had viro-
logic failure had nevirapine resistance at the 
time of failure. The results of the PENPACT 1 
study showed that NNRTI resistance in children 
with no response to NNRTI-based ART occurs 
early and at low levels of viral rebound (<1000 
copies per milliliter).4
Another potential contributing factor may 
have been the ramp-up dosing strategy, in which 
nevirapine is given once daily at half the final 
target dose for 2 weeks and is then increased to 
the full dose on a twice-daily schedule. This 
strategy was designed to minimize the risk of 
dermatologic reactions during the initiation of 
nevirapine therapy (seen primarily in adults dur-
ing drug development) and to accommodate the 
induction of cytochrome P-450 metabolizing en-
zymes after exposure to nevirapine. However, this 
may result in suboptimal levels of nevirapine 
during the ramp-up period, a time when viral 
levels in infected infants are profoundly elevated. 
This hypothesis is consistent with the finding 
that virologic failure in the nevirapine group 
tended to be an early event, occurring in the first 
12 to 24 weeks of therapy. The Children with 
Human Immunodeficiency Virus (HIV) in Africa 
— Pharmacokinetics and Adherence of Simple 
Antiretroviral Regimens (CHAPAS 1) study com-
pared the initiation of full-dose nevirapine in 
fixed-dose combination tablets to simplify ad-
ministration in children with a median age of 
5 years.7 Rash occurred at a higher frequency 
when nevirapine was initiated at the full dose 
(11%, vs. 2% with dose escalation) but was con-
sidered to be manageable.
Baseline resistance to NNRTIs due to unrec-
ognized exposure to drugs for preventing mother-
to-child transmission in cohort 2 is not likely to 
be responsible for the results; the frequency of 
baseline nevirapine resistance was less than 1% 
(1 of 132 children) in the nevirapine group. Re-
sistance was determined with the use of an HIV-
genotyping system based on population se-
quencing and approved by the Food and Drug 
Administration. Low-frequency NNRTI mutations, 
which can be detected only by means of high-
sensitivity assays, have been implicated in treat-
ment failure in adults.8,9 It is not known whether 
low-frequency mutations at baseline affected 
treatment outcomes in the P1060 cohort; this 
question will require further research. However, 
in the Nevirapine Resistance Study (NEVEREST), 
virologic failure in infants who were switched to 
nevirapine-based ART was associated with an 
increased frequency of baseline resistance, as 
detected by population sequencing, but not with 
low-frequency baseline resistance.10
Data from P1060 cohort 1 (infants exposed to 
single-dose nevirapine)1 and from NEVEREST11 
previously showed that CD4 counts and weight 
gain improved more slowly from baseline levels 
with ritonavir-boosted lopinavir than with nevi-
rapine despite efficacy data favoring ritonavir-
boosted lopinavir. Although somewhat counter-
intuitive, this observation was partially confirmed 
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in the present study, in which adjusted increases 
in the z score for weight and in BMI from base-
line to week 24 and to week 48 were signifi-
cantly larger in the nevirapine-treated group; 
however, changes in CD4+ counts over time ap-
peared to be similar in the two groups. The 
mechanism underlying the smaller weight gain 
in the ritonavir-boosted lopinavir group remains 
unclear, but leading hypotheses are poor palat-
ability and appetite suppression, as well as the 
metabolic consequences of ritonavir, excipients, or 
both in the liquid formulation (15.3% propylene 
glycol and 42.4% alcohol) or both.1,12-15
The path forward for pediatric first-line treat-
ment guidelines in resource-limited settings is 
not simple. Identification of HIV infection early 
in infancy, with prompt initiation of ART, is criti-
cal for increasing survival among HIV-infected 
children.3,16 The data from the P1060 cohort 2 
study show superior outcomes with ritonavir-
boosted lopinavir, as compared with nevirapine, 
for the composite end point, as well as for viro-
logic failure or death, toxicity, and death alone. 
These data support ritonavir-boosted lopinavir 
as the basis for first-line ART in all children 
younger than 3 years of age, regardless of 
whether they have had prior NNRTI exposure. 
Enthusiasm for such an approach, however, may 
be tempered by the inherent challenges to its 
implementation worldwide. For example, the 
liquid formulation of ritonavir-boosted lopinavir 
has an unpleasant taste and does not withstand 
high ambient temperatures. Today, the cost of a 
ritonavir-boosted lopinavir–based treatment reg-
imen for young children is approximately twice 
that of a nevirapine-based regimen. It is impor-
tant to note that 75% of the children who were 
randomly assigned to nevirapine had HIV-1 RNA 
levels below 400 copies per milliliter after 48 
weeks of therapy, although the percentage was 
higher for the children randomly assigned to 
ritonavir-boosted lopinavir. In the absence of a 
confirmatory study, policymakers are left to 
weigh the costs and benefits of these two differ-
ent first-line regimens as they develop national 
and regional pediatric treatment guidelines. New 
approaches to monitoring treatment and new 
drug formulations are urgently needed to ad-
dress this emerging gap in global pediatric HIV 
treatment.
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